Loading, Please Wait...
EL PASO, TX--(Marketwired - Apr 11, 2017) - Premier Biomedical, Inc. (
Greetings From The CEO and Staff at Premier Biomedical!
This past quarter has been a very busy and eventful one for Premier Biomedical.
Finance and Stock Performance
Immunotherapy and Biologics.
Investor/Public Relations Programs.
We are confident that we are in a high demand field and that we are on the cutting edge of pain product technology. We thank you for your continued support.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.